Dharmacon™ Accell™ siRNA References

Dharmacon™ Accell™ siRNA reagents are specially modified for use in difficult-to-transfect cells without the need for transfection reagents, virus, or electroporation. The following selected peer-reviewed publications have cited their successful use in a variety of experimental systems.

ARPE-19 (human retinal epithelial cells) - 40
BxPC3 (pancreatic tumor cell lines) - 10
C1 tumor derived cells – 53
Caco-2 (colon colorectal adenocarcinoma) – 28
E18 (Rat cortical neurons) - 1
GH3 (rat somatolactotrophs pituitary cell line) – 63
H9 stem cell lines – 50
HCT-116 (colorectal carcinomal) – 29
HUVEC – 30
JJN3 (plasma cell leukemia) – 45
MEC1 (human chronic B cell leukemia) – 15
MN-1 (mouse motor neuron) – 36
MS1 (mouse pancreatic islet endothelia cells) – 23
NOD CD4+CD25− splenic cells – 42
OVCA 420 (ovarian carcinomal) – 59
PGA-1 (lymphocytic leukemia B cell line) – 68
RAW264.7 macrophages – 56
SHSY5Y (neuroblastoma) – 13, 26, 67
SNB19 (glioma) – 14
T47D (ductal breast epithelial tumor cell line) – 24
T98 (glioma) – 14
THP-1 monocytes – 12, 27, 47, 52, 64
U266 (peripheral blood B lymphocyte myeloma) – 45
U937 (leukemic monocyte lymphoma) – 55
β-islet cells – 16
Bone marrow cells – 11, 18

Branchial smooth muscle cells (BSMC) – 31, 32
Cardiomyocytes – 6
CD4+ primary human T cells - 5
CD14+ primary monocytes – 22, 37
Cerebellar granule neurons (CGN) – 9
Cortical neurons – 2, 9, 46, 60
Endometrial cells – 17
Endothelial cells – 8, 38
Extravillous trophoblasts (EVT) – 33
Hepatocytes – 41, 43, 51
Immortalized B cells – 66
Keratinocytes – 58
Lymphocytes – 48
Macrophages – 4, 39, 54
Mantle cell lymphoma cells (MCL) – 49
Monocytes – 20
Mouse embryonic fibroblasts (MEF) – 25
Natural killer (NK) cell line – 62
Neurons (primary rat) – 21
Oligodendrocyte precursors – 61
Pancreatic tumor cell lines – 10
Peripheral blood mononuclear cells (PBMC) – 7, 35
Rat brain intracerebroventricular administration) - 70, 71
Vascular smooth muscle cells (VSMC) – 3, 65

*For more references that use our siRNA for in vivo applications, please see our in vivo siRNA reading list.
References:


44. E. Gonzalez-Gonzalez et al. Stripping of Reporter Gene Expression in Skin Using siRNAs and Expression of Plasmid DNA Delivered by a Soluble Protrusion Array Device (PAD). Molecular Therapy 18, 1667-74 (2010). [mouse intradermal injection]

45. B. Tunquist et al. Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor AVE9520. Molecular Cancer Therapeutics 9, 2046-2056 (2010). [multiple myeloma cell lines: RPMI 8226, JJN3, and U266 cells]


